190 related articles for article (PubMed ID: 10469215)
1. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.
Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y
Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma.
Momoi H; Itoh T; Nozaki Y; Arima Y; Okabe H; Satoh S; Toda Y; Sakai E; Nakagawara K; Flemming P; Yamamoto M; Shimahara Y; Yamaoka Y; Fukumoto M
J Hepatol; 2001 Aug; 35(2):235-44. PubMed ID: 11580146
[TBL] [Abstract][Full Text] [Related]
3. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
4. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma.
Kang YK; Kim WH; Lee HW; Lee HK; Kim YI
Lab Invest; 1999 Apr; 79(4):477-83. PubMed ID: 10212000
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.
Della Torre G; Pasquini G; Pilotti S; Alasio L; Civelli E; Cozzi G; Milella M; Salvetti M; Pierotti MA; Severini A
Diagn Mol Pathol; 2000 Mar; 9(1):41-6. PubMed ID: 10718212
[TBL] [Abstract][Full Text] [Related]
7. p53 and p21/Waf1 protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater.
Zhao B; Kimura W; Futakawa N; Muto T; Kubota K; Harihara Y; Takayama T; Makuuchi M
Am J Gastroenterol; 1999 Aug; 94(8):2128-34. PubMed ID: 10445539
[TBL] [Abstract][Full Text] [Related]
8. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
[TBL] [Abstract][Full Text] [Related]
11. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
12. Mutational landscape of intrahepatic cholangiocarcinoma.
Zou S; Li J; Zhou H; Frech C; Jiang X; Chu JS; Zhao X; Li Y; Li Q; Wang H; Hu J; Kong G; Wu M; Ding C; Chen N; Hu H
Nat Commun; 2014 Dec; 5():5696. PubMed ID: 25526346
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features.
Horie S; Endo K; Kawasaki H; Terada T
Virchows Arch; 2000 Jul; 437(1):25-30. PubMed ID: 10963376
[TBL] [Abstract][Full Text] [Related]
14. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand.
Kiba T; Tsuda H; Pairojkul C; Inoue S; Sugimura T; Hirohashi S
Mol Carcinog; 1993; 8(4):312-8. PubMed ID: 8280380
[TBL] [Abstract][Full Text] [Related]
15. [Genotyping of multiple genetic alterations of intrahepatic cholangiocarcinoma].
Cong W; Wu M; Chen H
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):271-3. PubMed ID: 11798885
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between genetic alterations and clinicopathological features in intrahepatic cholangiocarcinoma].
Cong W; Finkelstein SD; Wu M
Zhonghua Bing Li Xue Za Zhi; 2001 Jun; 30(3):183-7. PubMed ID: 11866974
[TBL] [Abstract][Full Text] [Related]
17. Correlation of p53 gene mutation and expression of P53 protein in cholangiocarcinoma.
Liu XF; Zhang H; Zhu SG; Zhou XT; Su HL; Xu Z; Li SJ
World J Gastroenterol; 2006 Aug; 12(29):4706-9. PubMed ID: 16937443
[TBL] [Abstract][Full Text] [Related]
18. [Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder].
Yu D; Liu F; Liang Z
Zhonghua Bing Li Xue Za Zhi; 1996 Aug; 25(4):202-5. PubMed ID: 9275651
[TBL] [Abstract][Full Text] [Related]
19. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.
Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M
Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950
[TBL] [Abstract][Full Text] [Related]
20. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma.
Yamaguchi K; Nakano K; Nagai E; Chijiiwa K; Kinoshita M; Ohta M; Tanaka M
Hepatogastroenterology; 2005; 52(63):713-8. PubMed ID: 15966189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]